New views on the complex interplay between degeneration and autoimmunity in multiple sclerosis

Area of Science:

• Neuroimmunology
• Neurodegeneration
• Pathophysiology of Multiple Sclerosis

Background:

• Multiple sclerosis (MS) is traditionally viewed as an autoimmune disorder due to inflammation and immune response.
• Current immunomodulatory therapies effectively manage relapses but show limited impact on MS progression.
• Neuropathological findings reveal significant degeneration and myelin loss during the progressive phase, when inflammation decreases.

Purpose of the Study:

• To challenge the prevailing autoimmune hypothesis of MS.
• To propose an alternative theory emphasizing a primary cytodegenerative process in MS pathogenesis.
• To explore the role of neurodegeneration and potential triggers like Epstein-Barr virus.

Main Methods:

• Review and synthesis of existing therapeutic data and clinical observations.
• Analysis of neuropathological findings in MS tissue.
• Exploration of parallels with other neurodegenerative disorders.

Main Results:

• Potent immunotherapies are less effective in the progressive stage of MS.
• Myelin and neuronal damage are most pronounced in later stages, coinciding with reduced inflammation.
• Clinical concepts like "progression independent of relapse activity" suggest early degenerative processes.

Conclusions:

• The autoimmune model may not fully explain MS, particularly its progressive phase.
• A primary cytodegenerative process targeting the myelinating unit could be the initial step in MS.
• This cytodegenerative process may be exacerbated by an autoimmune inflammatory response, with potential roles for Epstein-Barr virus and B cells.